DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Oxamic Acid is an investigational drug.
There have been 130 clinical trials for Oxamic Acid. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2013.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck Sharp & Dohme Corp., and M.D. Anderson Cancer Center.
There is one US patent protecting this investigational drug and eight international patents.
Recent Clinical Trials for Oxamic Acid
|Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)||Kavita Sarin||Phase 2|
|Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer||AstraZeneca||Phase 1|
|Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer||Jenny C. Chang, MD||Phase 1|
Top disease conditions for Oxamic Acid
Top clinical trial sponsors for Oxamic Acid
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Oxamic Acid||Start Trial||Process for the preparation of oxalyl- and oxamyl-hydrazides||Enichim ANIC S.p.A. (Palermo, IT)||Start Trial|
|Oxamic Acid||Start Trial||Novel fluorinated resorcinol ethers and their use as anti-allergics and anti-inflammatories||Ciba-Geigy Corporation (Ardsley, NY)||Start Trial|
|Oxamic Acid||Start Trial||Simultaneous assay for glucose and urea||Abbott Laboratories (Abbott Park, IL)||Start Trial|
|Oxamic Acid||Start Trial||N-acetylmannosamine dehydrogenase, process for its production, method for quantitatively analyzing N-acetylmannosamine or sialic acid, and kit for the quantitative analysis||Noda Institute for Scientific Research (Noda, JP)||Start Trial|
|Oxamic Acid||Start Trial||N,N'-hydrocarbylenebis[N-hals-substituted amic acid hydrazides] and their derivatives||Atochem North America, Inc. (Philadelphia, PA)||Start Trial|
|Oxamic Acid||Start Trial||Novel oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain||Meiji Seika Kaisha, Ltd. (JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Oxamic Acid||Austria||78246||2008-04-21||Start Trial|
|Oxamic Acid||Germany||68902078||2008-04-21||Start Trial|
|Oxamic Acid||European Patent Office||0338387||2008-04-21||Start Trial|
|Oxamic Acid||Spain||2042850||2008-04-21||Start Trial|
|Oxamic Acid||Greece||3005201||2008-04-21||Start Trial|
|Oxamic Acid||Italy||1218223||2008-04-21||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|